Cas:870822-88-1 ethyl 4-[1-[2-[(2-methylpropan-2-yl)oxycarbonyl]hydrazinyl]ethyl]benzoate manufacturer & supplier

We serve Chemical Name:ethyl 4-[1-[2-[(2-methylpropan-2-yl)oxycarbonyl]hydrazinyl]ethyl]benzoate CAS:870822-88-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

ethyl 4-[1-[2-[(2-methylpropan-2-yl)oxycarbonyl]hydrazinyl]ethyl]benzoate

Chemical Name:ethyl 4-[1-[2-[(2-methylpropan-2-yl)oxycarbonyl]hydrazinyl]ethyl]benzoate
CAS.NO:870822-88-1
Synonyms:tert-butyl 2-[1-[4-(ethoxycarbonyl)phenyl]ethyl]hydrazinecarboxylate
Molecular Formula:C16H24N2O4
Molecular Weight:308.37300
HS Code:2928000090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.097g/cm3
Index of Refraction:1.512
PSA:76.66000
Exact Mass:308.17400
LogP:3.73540

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like tert-butyl 2-[1-[4-(ethoxycarbonyl)phenyl]ethyl]hydrazinecarboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl 2-[1-[4-(ethoxycarbonyl)phenyl]ethyl]hydrazinecarboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl 2-[1-[4-(ethoxycarbonyl)phenyl]ethyl]hydrazinecarboxylate Use and application,tert-butyl 2-[1-[4-(ethoxycarbonyl)phenyl]ethyl]hydrazinecarboxylate technical grade,usp/ep/jp grade.


Related News: For seniors most in need of care, high-quality health care often is beyond reach. ChenMed brings concierge-style medicine — and better health outcomes — to the neediest populations. Physician-led and privately owned, ChenMed is a provider of choice for some 20 Medicare Advantage health insurance plans. [(2R,3R,4S,5R,6R)-3,5-Dihydroxy-2-hydroxymethyl-6-(2-trimethylsilanyl-ethoxy)-tetrahydro-pyran-4-yl]-acetic acid methyl ester manufacturers McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019. N-(5-Chloro-6-methyl-2-pyridin-2-yl-pyrimidin-4-yl)-N’-(5-trifluoromethyl-pyridin-2-yl)-ethane-1,2-diamine suppliers In the Phase III VICTORIA study, Verquvo met the primary efficacy objective based on a time-to-event analysis. 2-Methyl-3,4,7-triphenylphenanthro(9,10-e)-2H-azepin vendor & factory.